Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | GSR | P00390 | 1/20 | 0.33 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4785005 | 0.99 | TXNRD1 (0.35) | LMNASMN1; SMN2GSRTXNRD1 | |
| SCHEMBL4729402 | 0.83 | — | — | |
| SCHEMBL4731004 | 0.82 | — | — | |
| SCHEMBL6273903 | 0.81 | LMNA (0.39) | LMNASMN1; SMN2MAPTNPSR1GAA | |
| SCHEMBL1379797 | 0.80 | SMN1; SMN2 (0.39) | LMNASMN1; SMN2MAPTGAAGSR | |
| SCHEMBL4727146 | 0.74 | ALDH1A1 (0.42) | LMNASMN1; SMN2MAPT | |
| SCHEMBL10943626 | 0.74 | LMNA (0.39) | LMNASMN1; SMN2MAPTNPSR1GAA | |
| SCHEMBL4727950 | 0.74 | MAOA (0.44) | LMNAMAPT | |
| SCHEMBL10949964 | 0.74 | SMN1; SMN2 (0.39) | LMNASMN1; SMN2MAPTGAAGSR | |
| SCHEMBL10942288 | 0.74 | SMN1; SMN2 (0.39) | LMNASMN1; SMN2MAPTGAAGSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008021210-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| US-6979740-B2 | Process for preparation of ring-substituted 8-aminoquinoline analogs as antimalarial agents | NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH (IN) | 2005-12-27 | — | — | US | disclosed |
| EP-1606263-A1 | RING-SUBSTITUTED 8-AMINOQUINOLINE DERIVATIVES AS ANTIMALARIAL AGENTS | Council of Scientific and Industrial Research (IN) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004085402-A1 | RING-SUBSTITUTED 8-AMINOQUNOLINE DERIVATES AS ANTIMALARIAL AGENTS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2004-10-07 | — | — | WO | disclosed |
| US-20040192724-A1 | Process for preparation of ring-substituted 8-aminoquinoline analogs as antimalarial agents | NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH DEPARTMENT OF PHARMACEUTICAL TECHNOLOGY (IN) | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192724-A1 | Process for preparation of ring-substituted 8-aminoquinoline analogs as antimalarial agents | QDPR, SLC11A2, CYP2C8 | LMNA 1368/4885SMN1; SMN2 4098/4885MAPT 4223/4885 |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | LMNA 415/4885SMN1; SMN2 11/4885MAPT 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.